# Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer

> **NCT01637532** · PHASE1,PHASE2 · COMPLETED · sponsor: **Leiden University Medical Center** · enrollment: 21 (actual)

## Conditions studied

- Recurrent Ovarian Cancer

## Interventions

- **DRUG:** tocilizumab and interferon alpha 2-b
- **DRUG:** Carboplatin and Caelyx or doxorubicin

## Key facts

- **NCT ID:** NCT01637532
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2016-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01637532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01637532, "Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01637532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*